Evidence map›Paper›PMID 37935937›Full record

ArticleJournal of cancer research and clinical oncology2023

MicroRNA-367-3p directly targets RAB23 and inhibits proliferation, migration and invasion of bladder cancer cells and increases cisplatin sensitivity.

Xifeng Wei, Yuchen Jiang, Guanghua Yang, Taihao Chang, Guangyu Sun, Shuaiqi Chen, Shangrong Wu, Ranlu Liu

Open access · hybridAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Bladder cancer: non-coding RNAs and exosomal non-coding RNAs.Functional & integrative genomics · 2024
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Xifeng Wei *Department of Urology, The Second Hospital of Tianjin Medical University & Tianjin Institute of Urology, 23 Pingjiang Road, Hexi District, Tianjin, 300211, China.
Yuchen Jiang *Department of Urology, The Second Hospital of Tianjin Medical University & Tianjin Institute of Urology, 23 Pingjiang Road, Hexi District, Tianjin, 300211, China.
Guanghua Yang *Department of Urology, The Second Hospital of Tianjin Medical University & Tianjin Institute of Urology, 23 Pingjiang Road, Hexi District, Tianjin, 300211, China.
Taihao ChangDepartment of Urology, The Second Hospital of Tianjin Medical University & Tianjin Institute of Urology, 23 Pingjiang Road, Hexi District, Tianjin, 300211, China.
Guangyu SunDepartment of Urology, The Second Hospital of Tianjin Medical University & Tianjin Institute of Urology, 23 Pingjiang Road, Hexi District, Tianjin, 300211, China.
Shuaiqi ChenDepartment of Urology, The Second Hospital of Tianjin Medical University & Tianjin Institute of Urology, 23 Pingjiang Road, Hexi District, Tianjin, 300211, China.
Shangrong WuDepartment of Urology, The Second Hospital of Tianjin Medical University & Tianjin Institute of Urology, 23 Pingjiang Road, Hexi District, Tianjin, 300211, China.
Ranlu LiuDepartment of Urology, The Second Hospital of Tianjin Medical University & Tianjin Institute of Urology, 23 Pingjiang Road, Hexi District, Tianjin, 300211, China. ranluliu@126.com.
Second Hospital of Tianjin Medical University · CNTianjin Medical University · CNThe Fourth People's Hospital of Ningxia Hui Autonomous Region · CN

Funding

Natural Science Foundation of Ningxia Hui Autonomous Region, China No. 2022AAC03361Tianjin Science and Technology Planning Project, China No. 19ZXDBSY00050
6 · The paper itself

Abstract

objectivesThis study investigated the biological role of miR-367-3p upregulation in bladder cancer and verified the mutual relation between miR-367-3p and RAB23. MATERIALS AND

methodsExpression levels of miR-367-3p were determined by RT-qPCR in bladder cancer cell lines and human bladder cancer tissues. The effects of miR-367-3p on proliferation, migration and invasion were evaluated by cell colony formation assays, wound healing assays and trans-well assays, respectively. The effects of miR-367-3p and RAB23 on cisplatin sensitivity of bladder cancer cells were assessed by CCK-8 assay. The expression of its target-RAB23 was determined by western blotting in T24, 5637. Plasmids used in dual-luciferase assays were constructed to confirm the action of miR-367-3p on downstream target-RAB23 in T24 cells. And also, the role of miR-367-3p in tumorigenesis was also confirmed in nude mouse models.

resultsThe downregulation of miR-367-3p was observed in human bladder cancer tissues. MiR-367-3p downregulation positively correlated with tumor stage and tumor grade. MiR-367-3p overexpression in T24, 5637 cells suppressed the proliferation, migration, and invasion of bladder cancer cells in vitro while decreasing IC50 values under T24 and 5637 cisplatin treatment conditions. RAB23 was shown to be upregulated in bladder cancer tissues and cell lines. MiR-367-3p directly bound to the 3' UTR of RAB23 in T24 cells. RAB23 was potentially accounted for the aforementioned functions of miR-367-3p. Tumor formation experiments in nude mouse models confirmed that overexpression of miR-367-3p could inhibit tumor growth and invasion in vivo.

conclusionsmiR-367-3p acts as a tumor suppressor in bladder cancer by downregulating RAB23 signaling. We conjecture that miR-367-3p-mediated downregulation of RAB23 expression may be a new therapeutic strategy for bladder cancer treatment.

Indexed as

MicroRNAsUrinary Bladder Neoplasms3' Untranslated RegionsAnimalsCell Line, TumorCell MovementCell ProliferationCisplatinGene Expression Regulation, NeoplasticHumansMiceMice, Nuderab GTP-Binding Proteins3' Untranslated RegionsCisplatinMicroRNAsMIRN367 microRNA, humanMIRN367 microRNA, mouseRAB23 protein, humanrab GTP-Binding ProteinsBladder cancerCisplatin sensitivityMicroRNA-367-3pProliferationRAB23

Identifiers

PMID37935937
PMCPMC10725407
OpenAlexW4388476318

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.